Optimi Health Completes First GMP Psilocybin Export to UK for Phase 2 Clinical Trial

The dual-jurisdiction authorization underpinning Optimi Health Corp.'s first psilocybin shipment to the United Kingdom sets a procedural reference point for any CMO or sponsor organization mapping a regulatory pathway for psychedelic drug product supply into European clinical programs. The export, completed in June 2026, comprised psilocybin biomass and finished 5mg psilocybin capsules manufactured at Optimi's GMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence (DEL), and cleared under export authorization from Health Canada and import authorization from the UK Home Office.

The capsule formulation is identical to the product currently prescribed to patients in Australia under that country's Authorized Prescriber Scheme for treatment-resistant depression, a detail with direct relevance to process validation and comparability documentation. Producing both the biomass and the finished dosage form in-house, with API extracted via proprietary methods, means Optimi's supply chain sits within a single licensed facility, a configuration that simplifies batch record traceability and reduces the inter-site transfer risk that typically complicates multi-vendor psychedelic API supply.

For QA directors and regulatory affairs leads evaluating psychedelic clinical trial supply, the operational read is that a vertically integrated, single-site GMP model has now cleared a live two-regulator authorization test. The trial partner and therapeutic indication have not yet been disclosed; Optimi has stated both will be announced at a later date. The shipment follows a recently completed GMP production run, a portion of which was designated for European clinical research.

The broader manufacturing context matters here. Psychedelic drug products occupy a controlled substance tier that requires layered import and export licensing absent from conventional small-molecule supply chains. Optimi's ability to execute this shipment under its existing DEL, without a third-party API supplier, compresses the authorization surface area and offers a structural template that sponsors and CMOs entering this space will need to account for in their own technology transfer and site qualification planning.

The company also supplies finished MDMA drug products to regulated markets internationally, and accepts inquiries for special access program and clinical trial supply through its commercial channel. The Phase 2 trial's commencement timeline and primary endpoint structure will be the next measurable checkpoint against which Optimi's supply model can be evaluated.

Source: Optimi Health Corp. via GlobeNewswire (IBN), 10 June 2026.